LncRNA LINC00961 regulates endothelial-mesenchymal transition via the PTEN-PI3K-AKT pathway

JIN-XING HU1, ZE-QI ZHEN2, TING KANG1, WEI QIAN1, SHAN-HUA HUANG1 and BIN-GONG LI1,2

1Department of Cardiology, First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi 330033;
2Department of Cardiology, Qingdao Municipal Hospital, Qingdao, Shandong 266011, P.R. China

Received April 14, 2022; Accepted May 18, 2022

DOI: 10.3892/mmr.2022.12762

Abstract. The long noncoding RNA LINC00961 plays a crucial role in cancer and cardiovascular diseases. In the present study, the role and underlying mechanism of LINC00961 in endothelial-mesenchymal transition (EndMT) induced by transforming growth factor beta (TGF-β), was investigated. Human cardiac microvascular endothelial cells were transfected with LV-LINC00961 or short hairpin LINC00961 plasmids to overexpress or knock down LINC00961 in the cells, respectively. The cells were then exposed to TGF-β in serum-free medium for 48 h to induce EndMT. Flow cytometric analysis, cell counting Kit-8 assay and immunofluorescence staining were performed to examine the cell apoptosis rate, assess cell viability, and identify CD31+/α-SMA+ double-positive cells, respectively. Western blotting and reverse transcription-quantitative polymerase chain reaction were used to evaluate protein and mRNA expression, respectively. Injury to endothelial cells and EndMT was induced by TGF-β in a time-dependent manner. LINC00961 overexpression promoted injury and EndMT, whereas LINC00961 knockdown had the opposite effects. Knockdown of LINC00961 attenuated EndMT and injury to endothelial cells induced by TGF-β via the PTEN-PI3K-AKT pathway. Inhibition of LINC00961 expression may prevent the occurrence of EndMT-related cardiovascular diseases, such as myocardial fibrosis and heart failure. Therefore, LINC00961 shows potential as a therapeutic target for cardiovascular diseases.

Introduction

Acute myocardial infarction is an important and lethal cardiovascular disease characterised by a sharp decline in the coronary blood supply, and it typically develops into myocardial fibrosis (1-3). Previous studies on the regulatory mechanism of myocardial fibrosis following myocardial infarction showed that myocardial fibrosis is vital to disease progression (4,5).

Long non-coding RNAs (lncRNAs) are >200 nucleotides in length and do not have protein-coding ability. LINC00961 encodes a small polypeptide of amino acid response and is highly expressed in the heart tissue, where it regulates mTorC1 activation (6). Most researchers have focused on the ability of LINC00961 to inhibit various tumours (7-9) but recently began studying its cardiovascular effects. For example, Spencer et al (10) identified that LINC00961 and its encoded small polypeptide of amino acid response can regulate endothelial cell adhesion, proliferation and migration, among other processes. Liu et al (11) found that LINC00961, via the PTEN-AKT-GSK3β pathway, promoted myocardial infarction. Wu et al (12) demonstrated that LINC00961 contributed to coronary heart disease by regulating the function of vascular smooth muscle cells.

Markwald et al (13) first discovered endothelial-mesenchymal transition (EndMT) through heart formation developmental studies in 1975. EndMT plays an important role in pathophysiological processes such as myocardial ischemia-reperfusion, myocardial infarction, diabetic cardiomyopathy and fibrosis (14-17). EndMT can be induced by hypoxia and attenuated by activating AMP-activated protein kinase as well as by suppressing the mammalian target of rapamycin (mTOR) signalling pathway in human cardiac microvascular endothelial cells (HCMECs) (18-20).

Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is critical for cell growth and affects the survival and proliferation of tumour cells (21,22). PTEN is also associated with regenerative processes such as nerve injury recovery (23), cardiac ischemia (24) and wound healing (25). Yang et al (26) revealed that B lymphoma Mo-MLV insertion region 1 homolog aggravated myocardial fibrosis and reduced...
cardiac function after myocardial infarction by inhibiting the PTEN-P3K-AKT pathway.

Progress has been made in understanding the functions of LINC00961. However, whether it regulates EndMT remains unclear. In the present study, it was examined whether knockdown of LINC00961 attenuates EndMT and cell injuries by activating the PTEN-P3K-AKT pathway.

Materials and methods

**Cell culture, cell transfection and drug treatment.** HCMCs were obtained from ScienCell Research Laboratories, Inc. and cultured in 25-cm² cell culture flasks (Corning, Inc.) in a 5% CO₂ atmosphere at 37°C. The culture medium was Roswell Park Memorial Institute-1640 containing 10% fetal bovine serum (both from Gibco; Thermo Fisher Scientific, Inc.). Endothelial cells were used from passages 4 to 10 for the experiments.

Short hairpin RNA (shRNA) for LINC00961 and negative control sh-scramble were acquired from Wuhan Aspen Biotechnology co., ltd. The plasmid sequences were as follows: sh-LINC00961-1, 5'-AGTTGCCAGAACCTCTGGACCTTCA-3'; sh-LINC00961-2, 5'-CCUCAAGGGAUCCUUAU-3'; and sh-LINC00961-3, 5'-GCUCUUCAUGCUCCUA-3'. Lentiviruses (LV) carrying negative control scrambled RNA and shRNA were used for transfection at the optimal multiplicity of infection value. Transfection efficiency was measured at 450 nm with a microplate reader (Thermo Fisher Scientific, Inc.) after incubation for 2 h at 37°C, after which the absorbance was measured.

**Gene expression analysis.** Total RNA was extracted from HCMCs using TRIzol reagent (Invitrogen, CA, USA). Following RNA extraction, 1 μg of RNA was reverse transcribed using the HiScript III Reverse Transcriptase Kit (Vazyme, China). RT-qPCR was performed using the PrimeScript RT Reagent Kit (TaKaRa, Japan) and the KAPA SYBR Fast qPCR Master Mix (Kapa Biosystems, USA). The primer sequences are provided in Table I. The relative mRNA expression was normalized to the levels of GAPDH, and the fold change was calculated using the 2^-△△Ct method. The data were analyzed using the GraphPad Prism 6.0 software.

**Flow cytometric analysis.** Annexin V-FITC apoptosis detection kit (Sungene Biotech) was used to assess cell apoptosis according to the manufacturer's protocol. Cells were seeded into six-well plates (1x10⁵ cells/well) and cultured until reaching 85% confluence. After digestion, suspension and centrifugation (1,000 x g at 22°C for 3 min), the precipitate was washed with phosphate-buffered saline for 10 min, and the cells were fixed for 20 min at 4°C in 4% paraformaldehyde. The cells were then washed with PBS and permeabilized with 0.1% Triton X-100 for 10 min. After washing, the cells were stained with the primary antibody (1:5,000; cat. no. 14395-1-AP; ProteinTech Group, Inc.) or isotype control for 1 h with 5% bovine serum albumin (Gibco; Thermo Fisher Scientific, Inc.) and incubated overnight at 4°C with the primary antibody α-smooth muscle actin (α-SMA) and Alexa Fluor 647 goat anti-rabbit secondary antibodies. The cell samples were analyzed using a BD FACSaria III flow cytometer (BD Biosciences).

**Immunofluorescence staining.** Following fixation for 20 min at 4°C in 4% paraformaldehyde, the cells were washed with phosphate-buffered saline for 10 min, blocked for 1 h with 5% bovine serum albumin (Gibco; Thermo Fisher Scientific, Inc.) and incubated overnight at 4°C with the primary antibody α-SMA, fibroblast specific protein 1 (FSP-1), and β-catenin. Immunofluorescence was visualized using a Leica TCS SP8 confocal microscope.

| Table I. Primer sequences for quantitative PCR. |
|-----------------------------------------------|
| **Primer name** | **Primer sequence (5'-3')** |
|-----------------|-----------------------------|
| CD31 | F: ACCAAGATAGCCTTAAAGCTGGA R: TAAGAAATCCTGGCTGAGGAG |
| VE-Cadherin | F: AAGGACATAACACACGAGAACAG | R: GAGATGACCGCGAGTGAAGG AG |
| α-SMA | F: CTATGCTTCTGGACCGCACAACAG | R: CCCATACAGCACTGTAACCT |
| FSP-1 | F: GGTGTCCACCTTTCCAAGTACTG | R: TCTCTGGGCTGTATCTGG |
| Cyclin D1 | F: TCTACTTCAATGTGTCAGAAGG | R: CATTTAGGACCCAGGACCATG |
| Bel-2 | F: AGGATTGGCTCCTTGCAGAG | R: AGCCAGGAGAAATCAAACAGAG |
| Bax | F: TCTGAGCACATGCAAGGACAGG | R: ATCCCTTCGACCTCATTGTC |
| AKT | F: TTCTATGGGCTGGTATTGTTT | R: GCCGTAGTCTGTCCTCAG |
| PTEN | F: TGAGACAGCATTAGCACCCCCC | R: TACCAGTGATTGCTGACATG |
| LINC00961 | F: ATGGAAAGGCGACTTATGG | R: GGCGTCACATGAGGTACCAG |
| miTOR | F: AAGCCAAGCTCTTGTATTGGT | R: GGACGGGTAGGTAACAGGAT |
| PI3K | F: GTCCTATTGTCTGTCAATGGTG | R: TGGGTCTTCCAAATTCAACC |
| GAPDH | F: CATCATCCCTGCTCCATCTGG | R: GTGGGTCTGCGTGTAGGAAGTCC |

α-SMA, α-smooth muscle actin; FSP-1, fibroblast specific protein 1; PTEN, phosphatase and tensin homolog deleted on chromosome 10.
Molecular Medicine rePorTS  26:  246,  2022

(1:10,000; cat. no. AS1107; Aspen Biotechnology Co., Ltd.) at 22˚C, the cells were stained with 5 µg/ml DAPI (Beyotime Institute of Biotechnology) for 2 min at 22˚C. Fluorescence microscopy (BXM1; Olympus Corporation) was performed to visualise immunofluorescence.

Reverse transcription quantitative (RT‑q) PCR. Tripure Total rna e xtraction r eagent [ elK (Wuhan) Biotechnology co., ltd.] was used to isolate total rna from the HcMecs. all rT‑qPcr steps were conducted as previ ‑ously described (20,24). r elative expression changes were calculated using the 2 ‑ΔΔcq method (29), and the selected reference group was referenced as 1. The primers used in Pcr are listed in Table i .

Western blot analysis. Sodium dodecyl sulphate‑polyacrylamide gel electrophoresis (10%) was performed to separate proteins from the cells and mouse hearts. Western blot analysis was performed as previously described (20,24). details regarding the primary and secondary antibodies used are provided in Table ii. Statistical analysis. All analyses were performed using Prism 9.1.2 (GraphPad Software, Inc.) and SPSS 23.0 software (IBM Corp.). Unpaired t‑tests were used to compare differences between two groups. The data are presented as the means ± standard deviation; each experiment was repeated at least three times. P<0.05 was considered to indicate a statistically significant difference.

Results

Injury and EndMT in HCMECs induced by TGF‑β. As revealed in Fig. 1A, cell viability was reduced over time by TGF‑β. After 24 h of treatment with TGF‑β, cell viability in the TGF‑β group did not significantly differ from that in the control group (P>0.05). However, compared with the control group, the TGF‑β group exhibited significant differences in cell viability after 48, 72, and 96 h of treatment (P<0.05). Therefore, follow‑up experiments were performed using treatment with TGF‑β for 48 h. Treatment with TGF‑β for 48 h increased the apoptotic rate of endothelial cells (Fig. 1B). It was also revealed that the m rna and protein expression levels of α‑SMA and fibroblast specific protein 1 (FSP‑1) were elevated, whereas those of cd31 and V e‑cadherin (V e‑cad) were decreased after 48 h of TGF‑β treatment compared with the control group (Fig. 1C and D; P<0.05). Immunofluorescence used to assess the changes in cd 31 and α‑SMa expression levels showed the same trends as rT‑qPcr and western blot‑ting (Fig. 1e). These results revealed that the TGF‑β‑induced injury and EndMT model in H cMecs was successfully established by treatment with TGF‑β for 48 h.

LINC00961 knockdown attenuates apoptosis induced by TGF‑β in HCMECs. The expression of LINC00961 was suppressed in endothelial cells after transfection with the sh‑LINC00961‑1, sh‑LINC00961‑2 and sh‑LINC00961‑3 plasmids; the expression of LINC00961 was markedly increased using the ORF full‑length cDNA clone vector.

Table II. Information on primary and secondary antibodies.

| Antibodies          | Species  | Supplier                   | Catalogue number | Dilution |
|---------------------|----------|----------------------------|-------------------|----------|
| GAPDH               | Rabbit   | Abcam                      | ab37168           | 1:10,000 |
| PTEN                | Rabbit   | Abcam                      | ab267787          | 1:2,000  |
| p‑P13k              | Rabbit   | Abcam                      | ab182651          | 1:500    |
| P13k                | Rabbit   | Cell Signaling Technology, Inc. | 4292              | 1:3,000  |
| p‑AKT               | Rabbit   | Cell Signaling Technology, Inc. | 4060              | 1:1,000  |
| AKT                 | Rabbit   | Cell Signaling Technology, Inc. | 9272              | 1:2,000  |
| SPARR               | Rabbit   | Cell Signaling Technology, Inc. | 25823             | 1:1,000  |
| p‑mTOR              | Rabbit   | Cell Signaling Technology, Inc. | 5536              | 1:500    |
| mTOR                | Rabbit   | Cell Signaling Technology, Inc. | 2972              | 1:1,000  |
| CD31                | Mouse    | Santa Cruz Biotechnology, Inc. | sc‑376764         | 1:500    |
| VE‑Cadherin         | Rabbit   | Thermo Fisher Scientific, Inc. | 36‑1900           | 1:500    |
| α‑SMA               | Rabbit   | ProteinTech Group, Inc.     | 14395‑1‑AP        | 1:5,000  |
| FSP‑1               | Rabbit   | ProteinTech Group, Inc.     | 20886‑1‑AP        | 1:1,000  |
| Cyclin D1           | Rabbit   | Cell Signaling Technology, Inc. | 55506             | 1:1,000  |
| Bcl‑2               | Rabbit   | Abcam                      | ab59348           | 1:1,000  |
| Bax                 | Rabbit   | Cell Signaling Technology, Inc. | 2772              | 1:2,000  |
| HRP‑goat anti‑rabbit |        | Aspen Biotechnology Co., Ltd. | AS1107            | 1:10,000 |
| HRP‑goat anti‑mouse |        | Aspen Biotechnology Co., Ltd. | AS1106            | 1:10,000 |

p‑, phosphorylated; α‑SMA, α‑smooth muscle actin; FSP‑1, fibroblast specific protein 1; PTEN, phosphatase and tensin homolog deleted on chromosome 10; HRP, horseradish peroxidase.

p‑, phosphorylated; α‑SMA, α‑smooth muscle actin; FSP‑1, fibroblast specific protein 1; PTEN, phosphatase and tensin homolog deleted on chromosome 10; HRP, horseradish peroxidase.
LINC00961 levels were remarkably reduced following transfection of the sh-LINC00961-1 plasmid (Fig. 2A), and thus this plasmid was used in follow-up experiments. As revealed in Fig. 2B, LINC00961 expression was significantly increased in the TGF-β group but was significantly reduced in the sh-LINC00961 group compared with that in control group (P<0.05). LINC00961 knockdown recovered the cell viability that had been reduced by TGF-β, whereas LINC00961 overexpression exacerbated this reduction in cell viability (Fig. 2C; P<0.05). Flow cytometric analysis was performed to...
Figure 2. LINC00961 knockdown attenuates apoptosis induced by TGF-β in HCMECs. (A and B) Expression level of LINC00961 was determined using RT-qPCR. (C) Cell viability was examined using CCK-8 assay. (D) Rate of cell apoptosis was evaluated using flow cytometric analysis. (E) RT-qPCR was used to determine expression of apoptosis-related mRNA. (F) Western blotting to determine expression of apoptosis-related mRNA (a) Control, (b) TGF-β, (c) TGF-β + sh-LINC00961, (d) TGF-β + sh-Scramble, (e) TGF-β + LV-LINC00961 and (f) TGF-β + LV-Control. Each experiment was repeated at least three times. ns, P>0.05; *P<0.05 and #P<0.05. n=5 per group. HCMECs, human cardiac microvascular endothelial cells; RT-qPCR, reverse transcription-quantitative; CCK-8, Cell Counting Kit-8; sh, short hairpin; LV, lentivirus; ns, not significant.
detect the rate of apoptosis, which showed that LINC00961 overexpression further facilitated TGF-β-induced apoptosis. However, TGF-β-mediated apoptosis was reduced by LINC00961 knockdown (Fig. 2D). The mRNA transcription levels of the anti-apoptotic proteins Bcl-2 and cyclin D1 were decreased by TGF-β but were recovered when LINC00961 was knocked down, and further reduced when LINC00961 was overexpressed, whereas the mRNA transcription level of the proapoptotic protein Bax presented the opposite trend (Fig. 2E). In addition, western blotting was performed to assess changes in protein levels of Bax, Bcl-2 and Cyclin D1. It was identified that the protein levels exhibited similar trends as those of the mRNA transcription levels (Fig. 2F). These results indicated that TGF-β-mediated apoptosis was attenuated by LINC00961 knockdown.

**LINC00961 knockdown attenuates TGF-β-induced EndMT.**

As revealed in Fig. 3, the results of RT-qPCR and western
Molecular Medicine Reports 26: 246, 2022

blotting demonstrated that VE-cad and CD31 expression was significantly downregulated after TGF-β treatment compared with the control group (Fig. 3B and C; P<0.05). By contrast, FSP-1 and α-SMA expression levels were significantly upregulated (Fig. 3B and C; P<0.05) in the TGF-β group compared with those in the control group. VE-cad and CD31 expression levels were significantly upregulated (P<0.05), whereas FSP-1 and α-SMA levels were significantly downregulated (P<0.05) in the TGF-β + sh-LINC00961 group compared with those in the TGF-β group (Fig. 3B and C). The VE-cadherin and CD31 expression levels were significantly downregulated (P<0.05), whereas FSP-1 and α-SMA levels were significantly upregulated (P<0.05) in the TGF-β + LV-LINC00961 group compared with those in the TGF-β group (Fig. 3B and C). Immunofluorescence used to assess the changes in CD31 and α-SMA expression levels showed the same trends as RT-qPCR and western blotting (Fig. 3A). These data revealed that TGF-β-induced EndMT was attenuated by LINC00961 knockdown.

LINC00961 knockdown attenuates injury and EndMT in HCMECs by activating the PTEN-PI3K-AKT signalling pathway. Immunofluorescence staining indicated that α-SMA expression was significantly increased and CD31 expression was significantly decreased in the TGF-β + LV-LINC00961 group compared with that in the TGF-β group. CD31+ was significantly increased, whereas the α-SMA+ level was decreased significantly in the TGF-β + sh-LINC00961 group compared with that in the TGF-β group. However, the expression level was reversed when the TGF-β + sh-LINC00961 group was treated with VOT (Fig. 4A). As revealed in Fig. 4B, LINC00961 overexpression promoted cell apoptosis that had been affected by TGF-β. LINC00961 knockdown attenuated the cell apoptosis rate that had been affected by TGF-β; however, the rate of cell apoptosis was reversed when the LINC00961 knockdown group was treated with VOT. The RT-qPCR results demonstrated that PTEN mRNA transcription levels were significantly reduced (P<0.05) and the PI3K, AKT and mTOR mRNA transcription levels were significantly

Figure 4. LINC00961 knockdown attenuates injury and EndMT in HCMECs by activating the PTEN-PI3K-AKT signalling pathway. (A) Immunofluorescence staining was used to identify CD31+/α-SMA+ cells. α-SMA (red), CD31 (green); scale bars: 50 µm. (B) Rate of cell apoptosis was evaluated using flow cytometry. (C) Reverse transcription-quantitative PCR was used to determine the expression of PTEN, PI3K, AKT and mTOR mRNA. (D) Western blotting was used to determine the protein expression of PTEN, p-PI3K, PI3K, p-AKT, AKT, p-mTOR and mTOR. (a) TGF-β + sh-LINC00961, (b) TGF-β, (c) TGF-β + LV-LINC00961 and (d) TGF-β + sh-LINC00961 + VOT. Each experiment was repeated at least three times. ns, P>0.05; *P<0.05; **P<0.05 and ***P<0.05. n=5 per group. EndMT, endothelial-mesenchymal transition; HCMECs, human cardiac microvascular endothelial cells; PTEN, phosphatase and tensin homolog deleted on chromosome 10; α-SMA, α-smooth muscle actin; p-, phosphorylated; sh-, short hairpin; LV, lentivirus; VOT, VO-OHpic trihydrate; ns, not significant.
increased (P<0.05) in the TGF-β + LV-LINC00961 group compared with those in the TGF-β group (Fig. 4C). The RT-qPCR results also indicated that the PETN mRNA transcription level was decreased and PI3K, AKT and mTOR mRNA transcription levels were reduced (P<0.05) in the TGF-β + sh-LINC00961 group compared with those in the TGF-β group. However, these mRNA transcription levels were reversed when the TGF-β + sh-LINC00961 group was treated with VOT. In addition, western blotting was performed to examine changes in protein levels (Fig. 4D). According to the aforementioned data, LINC00961 knockdown by TGF-β induced injury and EndMT in HCMCs, possibly through activation of PTEN and inhibition of PI3K, AKT, and mTOR. The relationships among these proteins are schematically represented in Fig. 5.

**Discussion**

HCMCs play crucial physiological roles in maintaining the normal function of the heart, and their dysfunction leads to various cardiovascular diseases, such as ischemic cardiomyopathy, diabetic cardiomyopathy, myocardial infarction and heart failure (30-32). Human umbilical vein endothelial cells and human coronary artery endothelial cells have been used to investigate EndMT (33). To meet physiological requirements in vivo, HCMCs were used to evaluate EndMT. EndMT can be induced by TGF-β and hypoxia in HCMCs, and certain studies (18,34) showed that hypoxia can activate autophagy; therefore, TGF-β was used to induce EndMT to avoid the effect of autophagy. LncRNAs are associated with a range of cellular biological functions, such as RNA splicing, protein...
localisation and chromatin modification (35,36). Previously, Matsumoto et al (37) reported that LIN00961 generated SPAR polypeptide that acted via the lysosome to suppress amino-acid-mediated mTORC1 activity, thereby modulating skeletal muscle regenerative response following injury. Since their discovery, lncRNAs had reshaped our thinking on the design and regulatory landscape of genomes in metazoans. LncRNAs bear some of the hallmarks of mRNAs, as they are transcribed by RNA polymerase II, spliced, capped, and polyadenylated, yet they have been initially surmised to have little to no ORF information. LncRNAs were generally less widely expressed than mRNAs, thus raising the notion that they actively regulated specific biological processes (37). The efficacy of LIN00961 in inhibiting tumour growth, invasion and metastasis and regulating endothelial cell function has been extensively examined (9,38,39). The role of lncRNA LIN00961 has also gained attention in cardiovascular diseases (12,40,41). Based on the relationship between LIN00961 and cardiovascular diseases, the effect of this lncRNA on EndMT was examined in vitro and its underlying mechanisms were investigated.

During EndMT, the expression of related proteins is altered, including increased FSP-1 and SMA and decreased CD31 and VE-Cad (42). It was found that the protein expression of BAX, caspase, α-SMA and FSP-1 was increased, whereas that of Bcl-2, cyclin D1, CD31 and VE-cadherin was decreased in endothelial cells treated with TGF-β. LIN00961 knockdown reversed these alterations.

The PTEN inhibitor VOT was used to explore the underlying mechanism of LIN00961 in EndMT and cell injuries. LIN00961 knockdown downregulated the protein levels of p-Pi3K, p-AKT, and p-mTOR and upregulated the protein level of PTEN. When PTEN was inhibited using VOT, the effects of LIN00961 knockdown on p-Pi3K, p-AKT and p-mTOR were diminished. Based on these results, LIN00961 knockdown attenuated TGF-β-induced EndMT and cell injuries by activating the PTEN-PI3K-AKT pathway, which is consistent with the results of previous studies. For example, LIN00961 downregulation promotes the proliferation and inhibits the apoptosis of vascular smooth muscle cells (12). Liu et al (11) revealed that LIN00961 promoted myocardial infarction in the myocardial cell line H9c2. Considering the association of the PTEN-PI3K-AKT pathway with EndMT, LIN00961 has been considered as a diagnostic target to promote EndMT and myocardial fibrosis. In summary, LIN00961 knockdown attenuated endothelial cell injury and EndMT induced by TGF-β via the PTEN-PI3K-AKT signalling pathway. To confirm our results, further studies are needed to investigate the effects of LIN00961 in animal models and other cell lines (such as cardiomyocytes and fibroblasts). Additionally, other proteins related to the PTEN-PI3K-AKT pathway and EndMT and further methods should be used, including a luciferase assay.

In conclusion, it was revealed that LIN00961 knockdown attenuates injuries and EndMT in HCMECs in vitro by activating PTEN expression and inhibiting PI3K, AKT and mTOR expression. Inhibition of LIN00961 expression may prevent the occurrence of EndMT-related cardiovascular diseases, such as myocardial fibrosis and heart failure, and shows potential as a therapeutic target for cardiovascular diseases.

Acknowledgements
Not applicable.

Funding
The present study was supported by the Youth Project of Jiangxi Provincial Education Department Project (grant no. GJJ190129) and the National Natural Science Foundation of China.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
JXH performed the high-throughput sequencing experiments and the bioinformatics analysis. BGL, ZQZ, TK, WQ and SHH performed the histological examination of the kidney, and were major contributors in writing the manuscript. JXH and BGL confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Animal experiments were approved by the Laboratory Animal Ethics Committee of the First Affiliated Hospital of Nanchang University (Nanchang, China; approval no. 20210213).

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Talman V and Ruskoaho H: Cardiac fibrosis in myocardial infarction–from repair and remodeling to regeneration. Cell Tissue Res 365: 563-581, 2016.
2. Vaskova E, Ikeda G, Tada Y, Wahlquist C, Mercola M and Yang PC: Sacubitril/valsartan improves cardiac function and decreases myocardial fibrosis via downregulation of exosomal miR-181a in a rodent chronic myocardial infarction model. J Am Heart Assoc 9: e015640, 2020.
3. Liu W, Sun J, Guo Y, Liu N, Ding X, Zhang X, Chi J, Kang N, Liu Y and Yin X: Calhex231 ameliorates myocardial fibrosis post myocardial infarction in rats through the autophagy-NLRP3 inflammasome pathway in macrophages. J Cell Mol Med 24: 13440-13453, 2020.
4. Chi YC, Shi CL, Zhou M, Liu Y, Zhang G and Hou SA: Selective cyclooxygenase-2 inhibitor NS-398 attenuates myocardial fibrosis in mice after myocardial infarction via snail signaling pathway. Eur Rev Med Pharmacol Sci 21: 5805-5812, 2017.
5. Shihamoto M, Higo T, Naito AT, Nakagawa A, Sumida T, Okada K, Sakai T, Kuramoto Y, Yamaguchi T, Ito M, et al: Activation of DNA damage response and cellular senescence in cardiac fibroblasts limit cardiac fibrosis after myocardial infarction. Int Heart J 60: 944-957, 2019.
6. Tajaksh S: lncRNA-encoded polypeptide SPARs with mTORC1 to regulate skeletal muscle regeneration. Cell Stem Cell 20: 428-430, 2017.
7. Mu X, Mou KH, Ge R, Han D, Zhou Y and Wang LJ: Linc00961 inhibits the proliferation and invasion of invasion by targeting the miR367/PTEN axis. Int J Oncol 55: 708-720, 2019.
8. Wu H, Du Q, Zhang D, Zhang X, He C, Xie X and Cai C: LINC00961 inhibits the migration and invasion of colon cancer cells by sponging miR-223-3p and targeting SOX11. Cancer Med 9: 2514-2523, 2020.
9. Zhang L, Shao L and Hu Y: Long noncoding RNA LINC00961 inhibited cell proliferation and invasion through regulating the Wnt/beta-catenin signaling pathway in tongue squamous cell carcinoma. J Cell Biochem 120: 12429-12435, 2019.
10. Spencer Hl, Sanders R, Boulberdaa M, Meloni M, Cochrane A, Spiroki AM, Mountford J, Emanuelli C, Caporali A, Brittan M, et al: The LINC00961 transcript and its encoded micropeptide LINC00961AAR regulate endothelial cell function. Cardiovasc Res 116: 1981-1994, 2020.
11. Liu S, He Y, Shi J, Liu M, Ma H, He L and Guo Y: STAT1-avtivated LINC00961 regulates myocardial infarction by the PI3K/ Akt/GSK3β signaling pathway. J Cell Biochem 120: 13226-13236, 2020.
12. Wu CT, Liu S and Tang M: Downregulation of linc00961 contributes to promote proliferation and inhibit apoptosis of vascular smooth muscle cell by sponging miR-367 in patients with coronary heart disease. Eur Rev Med Pharmacol Sci 23: 11310-11318, 2019.
13. Markward RR, Fitzharris TP and Smith WN: Structural analysis of endocardial cytodifferentiation. Dev Biol 462: 160-180, 1975.
14. Liu X, Mujahid H, Rong B, Lu QH, Zhang W, Li P, Li N, Liang ES, Wang Q, Tang DQ, et al: Irisin inhibits high glucose-induced endothelial-to-mesenchymal transition and exerts a dose-dependent bidirectional effect on diabetic cardiomyopathy. J Cell Mol Med 22: 808-822, 2018.
15. Feng B, Cao Y, Chen S, Chu X, Chu Y and Chakrabarti S: miR-200b mediates endothelial-to-mesenchymal transition in diabetic cardiomyopathy. Diabetes 65: 768-779, 2016.
16. Yin Y, Zhang Q, Qiao Z, Ding G, Wei C, Chang L, Li H, Bei H, Wang H, Liang J and Jia Z: Tungxilin attenuates myocardial fibrosis after acute myocardial infarction in rats via inhibition of endothelial-to-mesenchymal transition. BioMed Res Int 16: 6595437, 2019.
17. Zheng X, Peng M, Li Y, Wang X, Lu W, Wang X, Shan Y, Li R, Gao L and Cqu C: Cathelicidin-related antimicrobial peptide protects against cardiac fibrosis in diabetic mice heart by regulating endothelial-mesenchymal transition. Int J Biol Sci 15: 2393-2407, 2019.
18. Zou J, Liu Y, Li B, Zheng Z, Ke X, Hao Y, Li X, Li X, Liu F and Zhang Z: Autophagy attenuates endothelial-to-mesenchymal transition by promoting snail degradation in human cardiac microvascular endothelial cells. Biosci Rep 37: BSR201710497, 2017.
19. Liu Y, Zou J, Li B, Wang Y, Wang D, Hao Y, Ke X and Li X: RUNX3 modulates hypoxia-induced endothelial-to-mesenchymal transition in human cardiac microvascular endothelial cells. Int J Mol Med 40: 65-74, 2017.
20. Hu J, Zheng Z, Li X, Li B, Lai X, Li N and Lei S: Metformin attenuates hypoxia-induced endothelial cell injury by activating the AMP-activated protein kinase pathway. J Cardiovasc Pharmacol 77: 862-874, 2021.
21. Gao X, Qin T, Mao J, Zhang J, Fan S, Lu Y, Sun Z, Zhang Q, Song B and Li L: PTEN/Pi3K/mTOR axis contributes to breast cancer progression by regulating PTEN via PI3K/ AKT pathway. Int J Exp Clin Cancer Res 38: 256, 2019.
22. Chai C, Song LJ, Hai SY, Li XQ and Li M: MicroRNA-21 promotes myocardial cell proliferation and inhibits fibrosis and apoptosis by targeting SPRY1 via the PI3K/AKT signaling pathway. CNS Neurosci Ther 24: 369-380, 2018.
23. Hervara A, De Virgilis F, Palmasino I, Zhou L, Tantardini E, Kong G, Hutson T, Danzi MC, Perry RB, Santos CXC, et al: Reactive oxygen species regulate axonal regeneration through the release of exosomal NADPH oxidase 2 complexes into injured axons. Nat Cell Biol 20: 307-319, 2018.
24. Cheng S, Zhang X, Feng Q, Chen J, Shen L, Yu P, Yang L, Chen D, Zhang H, Sun W and Chen X: Agranulosaoxid 4E exerts angiogenesis and cardiac protection after myocardial infarction via regulating PTEN/Pi3K/Akt signaling pathway. Life Sci 227: 82-93, 2019.
25. Cao L, Graue-Hernandez EO, Tran V, Reid B, Pu J, Mannis NJ and Zhao M: Downregulation of PTEN at cardiac wound sites accelerates wound healing through increased cell migration. Invest Ophthalmol Vis Sci 52: 2272-2278, 2011.